Biosaintifika J
Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs
Eli Lilly and Company (LLY) on Wednesday said that its oral GLP-1 drug Orforglipron lowered blood glucose levels in two late-stage trials, confirming its potential in treating type-2 diabetes
In normal human physiology, GLP-1 and GIP are released by the gastrointestinal tract (enteroendocrine L cells in the small intestine and colon and enteroendocrine K cells respectively) in response to nutrient intake and have half-lives of 1 to 3 min [36]
The semaglutide case exemplifies how the patent system has been turned into a key instrument of the pharmaceutical industrys financialized business model
Obese patients in the real world tend not to be very compliant and not to follow the lifestyle change recommendations needed to show the promise delivered during clinical trials